Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Shares Issued (2023 - 2025)

Compass Therapeutics' Shares Issued history spans 3 years, with the latest figure at $138.0 million for Q3 2025.

  • For Q3 2025, Shares Issued changed N/A year-over-year to $138.0 million; the TTM value through Dec 2025 reached $138.0 million, changed N/A, while the annual FY2025 figure was $138.0 million, N/A changed from the prior year.
  • Shares Issued for Q3 2025 was $138.0 million at Compass Therapeutics, up from -$18.1 million in the prior quarter.
  • Across five years, Shares Issued topped out at $138.0 million in Q3 2025 and bottomed at -$18.1 million in Q4 2024.
  • The 3-year median for Shares Issued is $1.6 million (2023), against an average of $17.6 million.
  • The largest YoY upside for Shares Issued was 44046.34% in 2024 against a maximum downside of 691.16% in 2024.
  • A 3-year view of Shares Issued shows it stood at $3.1 million in 2023, then crashed by 691.16% to -$18.1 million in 2024, then surged by 861.88% to $138.0 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Shares Issued are $138.0 million (Q3 2025), -$18.1 million (Q4 2024), and $13000.0 (Q2 2024).